Drugs / STW5-II
STW5-II
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02246686 | Nov 2014 → Feb 2015 | ulcerative colitis | Bayer | Terminated | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT07198243 | Sep 2025 → Dec 2028 expected | dyspepsia | Universitaire Ziekenhuizen KU Leuven | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04656730 | Sep 2020 → Jan 2023 | dyspepsia, irritable bowel syndrome | Hospital Vall d'Hebron | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STW 5-II | “STW5-II (Iberogast N®) is an herbal medicinal preparation consisting of six herbal extracts” NCT04656730 ↗3“supports the favorable benefit risk profile of BAY98-7410 (STW 5-II)” NCT04656730 ↗ |
| Known as | BAY98-7410 | “supports the favorable benefit risk profile of BAY98-7410 (STW 5-II)” NCT04656730 ↗1“STW5-II (Iberogast N, BAY98-7410)” NCT02246686 ↗ |
| Known as | Iberogast N | “STW5-II (Iberogast N®) is an herbal medicinal preparation consisting of six herbal extracts” NCT04656730 ↗1“STW5-II (Iberogast N, BAY98-7410)” NCT02246686 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “STW5-II (Iberogast N®) is an herbal medicinal preparation consisting of six herbal extracts” NCT04656730 ↗ |
| Route | Oral | “Oral intake of the investigation drug 20 drops three times per day (TID) for 14 days” NCT04656730 ↗ |